Lercanidipine Hcl Aurobindo

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Hcl Aurobindo, is a calcium channel blocker (dihydropyridine) presented as an oral tablet for oral use. It treats hypertension by relaxing vascular smooth muscle and lowering blood pressure. GNH USA supplies Lercanidipine Hcl Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a calcium channel blocker used to manage conditions related to elevated blood pressure. Hypertension: lowers systolic and diastolic blood pressure in patients with high blood pressure.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the lower limbs due to fluid accumulation. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate in some patients. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of face, lips, or throat requiring urgent care. - Hepatic dysfunction: abnormal liver enzyme elevations. - Life‑threatening arrhythmia: abnormal heart rhythm that can be fatal.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific concerns. - Blood pressure monitoring: regularly assess to ensure therapeutic effect and avoid excessive drop. - Cardiovascular assessment: evaluate for underlying heart disease before use. - Hepatic impairment: use with caution in patients with liver dysfunction. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of hypotension. - Concomitant use with other antihypertensives: can cause additive blood pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug effectiveness. - Grapefruit juice: can raise lercanidipine levels, increasing side‑effect risk. - NSAIDs: may enhance peripheral edema when combined with lercanidipine.